Abstract: The present disclosure is directed, in part, to pharmaceutical compositions comprising a Src protein tyrosine kinase inhibitor, an ATP citrate lyase (ACLY) inhibitor, and a PI3K inhibitor, and/or a Src and PIP2/PIP3 inhibitor of binding to ACLY, and a pharmaceutically acceptable carrier, methods of identifying a compound as a potential therapeutic agent for treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway in a cell, and methods of treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway.